Virus de hepatitis B y C. Retos en su tratamiento: [Editorial]

Alvarez, Carlos; Valderrama, Sandra.
Infectio ; 20(3): 121-122, jul.-sep. 2016.
Artigo em Espanhol | LILACS | ID: lil-791160

Documentos relacionados

  1. Factors Associated with the Refusal of Direct-Acting Antiviral Agents for the Treatment of Hepatitis C in Taiwan.
  2. Viral Hepatitis, Cholesterol Metabolism, and Cholesterol-Lowering Natural Compounds.
  3. Hepatitis B surface antibody titres and hepatitis B reactivation with direct-acting antiviral therapy for hepatitis C.
  4. Low-dose nivolumab in advanced hepatocellular carcinoma.
  5. A hepatitis B virus causes chronic infections in equids worldwide.
  6. [Mechanism and clinical significance of HBV reactivation after anti-HCV therapy].
  7. HIV, hepatitis B & C in people who inject drugs in India: A systematic review of regional heterogeneity & overview of opioid substitution treatment.
  8. A Phase 2 open label study of ledipasvir/sofosbuvir for 12 weeks in subjects with hepatitis B virus infection.
  9. Serum cytokine/chemokine profiles predict hepatitis B reactivation in HBV/HCV co-infected subjects receiving direct-acting antiviral agents.
  10. Current management of children with hepatitis C virus mother-to-child transmission.